2024
Meningeal lymphatic vessel dysfunction driven by CGRP signaling causes migraine-like pain in mice
Thomas J, Schindler E, Gottschalk C. Meningeal lymphatic vessel dysfunction driven by CGRP signaling causes migraine-like pain in mice. Journal Of Clinical Investigation 2024, 134: e182556. PMID: 39087472, PMCID: PMC11290958, DOI: 10.1172/jci182556.Peer-Reviewed Original ResearchConceptsBlocking CGRP signalingCGRP receptor componentsMigraine-like painCervical lymph nodesGap junction proteinPrimary headache disordersLymphatic vessel dysfunctionAcute migrainePharmacological blockadeLymph nodesHeadache disordersNeurological symptomsJunction proteinsCGRPLymphatic vesselsMeningeal lymphatic vesselsInducible knockoutVessel dysfunctionMigraineReceptor componentsHeadachePainPathophysiologyDysfunctionMice
2023
The Potential of Psychedelics for the Treatment of Episodic Migraine
Schindler E. The Potential of Psychedelics for the Treatment of Episodic Migraine. Current Pain And Headache Reports 2023, 27: 489-495. PMID: 37540398, DOI: 10.1007/s11916-023-01145-y.Peer-Reviewed Original ResearchConceptsEpisodic migrainePotential of psychedelicsWeekly migraine daysPsychedelic drugsMigraine daysPain intensityTransitional treatmentCluster headacheHeadache disordersPreventive effectClinical trialsSingle administrationTherapeutic effectAbortive effectMigrainePsychiatric conditionsReviewThis reviewTherapeutic agentsDrugsAdditional findingsMedicinal usePsychedelicsTreatmentPotential medicinal usePsilocybinUnderstanding headache classification coding within the veterans health administration using ICD-9-CM and ICD-10-CM in fiscal years 2014–2017
Fodeh S, Fenton B, Wang R, Skanderson M, Altalib H, Kuruvilla D, Schindler E, Haskell S, Brandt C, Sico J. Understanding headache classification coding within the veterans health administration using ICD-9-CM and ICD-10-CM in fiscal years 2014–2017. PLOS ONE 2023, 18: e0279163. PMID: 36598881, PMCID: PMC9812322, DOI: 10.1371/journal.pone.0279163.Peer-Reviewed Original ResearchConceptsVeterans Health AdministrationHeadache diagnosisICD-10-CMICD-10-CM diagnosisICD-10-CM codingSpecialty care clinicsSpecific headache diagnosesICD-9-CM codingDifferent headache typesICD-9-CMRace/ethnicityHeadache comorbidityHeadache NOSPatient ageCare clinicsChronic conditionsHeadache typesProvider typeSociodemographic factorsHealth AdministrationDiagnosisTwo yearsHeadachePatientsMigraine
2020
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D'Souza D. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics 2020, 18: 534-543. PMID: 33184743, PMCID: PMC8116458, DOI: 10.1007/s13311-020-00962-y.Peer-Reviewed Original ResearchConceptsTherapeutic effectAdverse eventsSingle administrationPsychotropic effectsWeekly migraine daysSerious adverse eventsCross-over studyEffects of psilocybinOral placeboMigraine daysMigraine frequencyClinical effectsControlled StudyHeadache disordersMigraine headacheHeadache diaryDrug effectsDrug AdministrationNeuropsychiatric conditionsMigraineFinal analysisStudy proceduresReceptor ligandsWeeksAdministration